Search results for "Colitis"

showing 10 items of 483 documents

Intestinal Ischemia: US-CT findings correlations.

2013

Background Intestinal ischemia is an abdominal emergency that accounts for approximately 2% of gastrointestinal illnesses. It represents a complex of diseases caused by impaired blood perfusion to the small and/or large bowel including acute arterial mesenteric ischemia (AAMI), acute venous mesenteric ischemia (AVMI), non occlusive mesenteric ischemia (NOMI), ischemia/reperfusion injury (I/R), ischemic colitis (IC). In this study different study methods (US, CT) will be correlated in the detection of mesenteric ischemia imaging findings due to various etiologies. Methods Basing on experience of our institutions, over 200 cases of mesenteric ischemia/infarction investigated with both US and …

medicine.medical_specialtyRadiological and Ultrasound TechnologyIleusmedicine.diagnostic_testbusiness.industryResearchIschemiaInfarctionInterventional radiologymedicine.diseaseVenous ObstructionIschemic colitisMesenteric ischemiaInternal medicinemedicineCardiologyRadiologycardiovascular diseasesbusinessReperfusion injury
researchProduct

Is 5-ASA Still the Treatment of Choice for Ulcerative Colitis?

2010

5-Amino-salacylic acid (5-ASA) is up to now the treatment of choice in the induction and maintenance of remission of mild-to-moderate ulcerative colitis (UC). Sulfasalazine, despite similar efficacy, is hampered by more side effects, but in presence of peripheral arthopaties it remains the treatment of choice. The new delayed release MMX formulation seems to be promising in reducing compliance problems, but further studies are warranted to show the superiority of new MMX formulation compared with the older formulations of 5-ASA. Some trials evaluated also the efficacy and safety of once-daily dosing of older 5-ASA formulations in maintenance of remission, finding a greater adherence to ther…

medicine.medical_specialtySettore MED/09 - Medicina InternaClinical BiochemistryPharmacologyPlaceboSulfasalazineInternal medicineDrug DiscoverymedicineHumansDosingColitisMesalamine5-ASA Treatment Choice Ulcerative ColitisPharmacologyClinical Trials as Topicbusiness.industryAnti-Inflammatory Agents Non-Steroidalmedicine.diseaseUlcerative colitisTacrolimusRegimenMolecular MedicineColitis UlcerativeRosiglitazonebusinessmedicine.drugCurrent Drug Targets
researchProduct

Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease

2014

Many placebo controlled trials and meta-analyses evaluated the efficacy of different drugs for the treatment of inflammatory bowel disease (IBD), including immunosuppressants and biologics. Their use is indicated in moderate to severe disease in non responders to corticosteroids and in steroid-dependent patients, as induction and maintainance treatment. Infliximab, as well as cyclosporine, is considered a second line therapy in the case of severe ulcerative colitis, or non-responders to intravenous corticosteroids. An adequate dosage and duration of therapy with thiopurines should be reached before evaluating their efficacy. Methotrexate is a valid option in patients with Crohn’s disease bu…

medicine.medical_specialtySettore MED/09 - Medicina InternaCombination therapyInflammatory bowel diseaseGastroenterologyimmunosuppresantbiologicsinflammatory bowel diseaseCrohn DiseaseGastrointestinal AgentsRisk FactorsInternal medicinemedicineimmunomodulators.optimization. treatmentHumansTopic HighlightBiological ProductsGastrointestinal agentCrohn's diseaseThiopurine methyltransferasebiologybusiness.industryGastroenterologyGeneral Medicinemedicine.diseaseUlcerative colitisTacrolimusInfliximabSurgeryTreatment Outcomebiology.proteinColitis UlcerativeDrug Therapy CombinationbusinessImmunosuppressive Agentsmedicine.drug
researchProduct

Inflammation and Aortic Stiffness: An Individual Participant Data Meta‐Analysis in Patients With Inflammatory Bowel Disease

2017

Background The recent finding that aortic pulse wave velocity ( aPWV ) is increased in patients with inflammatory bowel disease may explain why the cardiovascular risk is increased despite the low prevalence of traditional cardiovascular risk factors. We aimed to test whether inflammation is associated with aortic stiffening in this setting after adjustment for major confounders and to perform subgroup analyses. Methods and Results A systematic literature search for aPWV in inflammatory bowel disease was performed using PubMed, Scopus, Web of Science, and Google Scholar databases (last accessed May 7, 2017). Inclusion criterion was peer‐reviewed publications on clinical studies reporting o…

medicine.medical_specialtySettore MED/09 - Medicina Internapulse wave velocitycardiovascular complicationsBlood SedimentationPulse Wave Analysis030204 cardiovascular system & hematologyStandard scoreInflammatory bowel diseaseLeukocyte Count03 medical and health sciencesVascular Stiffness0302 clinical medicineCrohn DiseaseRisk FactorsInternal medicinemedicineHumansArterial stiffness; Cardiovascular complications; Crohn's disease; Inflammation; Pulse wave velocity; Ulcerative colitis; Cardiology and Cardiovascular Medicine030212 general & internal medicineulcerative colitisInflammationSystematic Review and Meta‐AnalysisCrohn's diseasemedicine.diagnostic_testbusiness.industryMeta Analysisinflammation aortic stiffnessPrognosismedicine.diseaseUlcerative colitisConfidence intervalCrohn's diseaseC-Reactive Proteinarterial stiffnessCardiovascular DiseasesMeta-analysisErythrocyte sedimentation rateMultivariate AnalysisHypertensionLinear ModelsPhysical therapyArterial stiffnessColitis UlcerativeInflammation MediatorsCardiology and Cardiovascular MedicinebusinessBiomarkersJournal of the American Heart Association
researchProduct

Smoking therapy may be an extreme cure in exsmokers with steroid-dependent and resistant ulcerative colitis.

2011

medicine.medical_specialtySteroid dependencySettore MED/09 - Medicina Internabusiness.industryInternal medicineSmoking therapyexsmokers steroid-dependentulcerative colitisGastroenterologymedicineImmunology and Allergymedicine.diseasebusinessUlcerative colitisGastroenterology
researchProduct

Responses to self and non-self intestinal microflora in health and inflammatory bowel disease.

1997

medicine.medical_specialtyT-LymphocytesImmunologyBiologyCross ReactionsInflammatory bowel diseaseGastroenterologyAntibodiesImmune tolerancePathogenesisMiceImmune systemCrohn DiseaseInternal medicinemedicineAnimalsHumansCrohn diseaseCross reactionsmedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisInterleukin-12Interleukin-10IntestinesInterleukin 10Disease Models AnimalImmunologyForecastingResearch in immunology
researchProduct

A Web-Based Telemanagement System for Patients With Complex Inflammatory Bowel Disease: Protocol for a Randomized Controlled Clinical Trial

2018

Background: Telemedicine has been successfully used to provide inflammatory bowel disease (IBD) patients with health care services remotely via the implementation of information and communications technology, which uses safe and feasible apps that have been well accepted by patients in remission. However, the design of telemedicine apps in this setting involves difficulties that hinder the adherence of patients to the follow-up plans and the efficacy of these systems to improve disease activity and quality of life. Objective: This study aimed to evaluate the development of a Web platform, Telemonitoring of Crohn Disease and Ulcerative Colitis (TECCU), for remote monitoring of patients with …

medicine.medical_specialtyTelemedicine020205 medical informatics02 engineering and technologyInflammatory bowel diseaselaw.invention03 medical and health sciences0302 clinical medicineQuality of life (healthcare)information technologyRandomized controlled trialinflammatory bowel diseaselawHealth careProtocol0202 electrical engineering electronic engineering information engineeringmedicineeHealthDisease management (health)Intensive care medicineulcerative colitisbusiness.industryCrohn diseaseGeneral Medicinemedicine.diseaseClinical trialeHealth030211 gastroenterology & hepatologytelemedicinebusinessJMIR Research Protocols
researchProduct

Use of telemedicine in inflammatory bowel disease: a real monitoring option?

2016

Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn’s disease (CD), is a chronic and relapsing disorder characterized by inflammation of the gastrointestinal tract. The natural progression includes periods of flares and remission, requiring continuous and personalized follow-up to achieve long remission and minimize short and long term damage. In fact, IBD patients show significantly higher rates of utilization of healthcare resources than patients with other conditions [1]. It is important to emphasize that 30-45% of adults are nonadherents [2], making these patients five times more likely to suffer relapses and consequently increasing health care costs [3]. …

medicine.medical_specialtyTelemedicineHealth Knowledge Attitudes PracticeDiseaseInflammatory bowel diseaseGastroenterology03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Internal medicineHealth caremedicineHumansIntensive care medicineCrohn's diseaseHepatologybusiness.industryWork disabilityAttitude to ComputersDelivery of Health Care IntegratedRemote ConsultationGastroenterologyPatient Acceptance of Health Caremedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisdigestive system diseasesTelemedicineTreatment Outcome030220 oncology & carcinogenesis030211 gastroenterology & hepatologybusinessExpert review of gastroenterologyhepatology
researchProduct

DOP41 Efficacy and safety of open-label treatment with tofacitinib 10 mg twice daily in patients with ulcerative colitis with clinical response, but …

2019

medicine.medical_specialtyTofacitinibOctave (poetry)business.industryOPEN LABEL TREATMENTGastroenterologyGeneral Medicinemedicine.diseaseUlcerative colitisMaintenance therapyInternal medicinemedicineIn patientbusinessJournal of Crohn's and Colitis
researchProduct

OP29 Tofacitinib in ulcerative colitis: Real-world evidence from Eneida Registry

2020

Abstract Background Our aim was to evaluate the effectiveness and safety of tofacitinib in ulcerative colitis (UC) in real life. Methods Patients from the prospectively maintained ENEIDA registry treated with tofacitinib due to active UC were included. Clinical activity and effectiveness were defined based on Partial Mayo Score (PMS). The short-term response was assessed at week 4, 8 and 16. The last-observation-carried-forward method was used in patients that stopped tofacitinib before the time-points for clinical assessment. Variables associated with short-term remission at week 8 were identified by logistic regression analysis. The cumulative retention rate and the cumulative incidence o…

medicine.medical_specialtyTofacitinibbusiness.industryHypertriglyceridemiaGastroenterologyGeneral MedicineReal world evidencemedicine.diseaseUlcerative colitisInternal medicineDisease remissionmedicinePredictor variableAdverse effectbusinessSurvival analysisJournal of Crohn's and Colitis
researchProduct